EBS

Emergent BioSolutions Inc.

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through their specialty products and contract development and manufacturing services, the company is dedicated to providing solutions that address public health threats. Through social responsibility, Emergent BioSolutions aims to build healthier and safer communities. The company aspires to deliver peace of mind to theis patients and customers so they can focus on what\'s most important in their lives. In working together, Emergent envisions protecting or enhancing 1 billion lives by 2030.

Emergent BioSolutions Inc. (EBS) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Profitability (C).

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B
Factor Score 3.4 / 5.0
Growth
C+
Factor Score 2.6 / 5.0
Profitability
C
Factor Score 2.4 / 5.0
Momentum
B-
Factor Score 2.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 5.8
EV / EBITDA 5.2
Rev Growth YoY -52.4%
Gross Margin 43.4%
Price Return 3M 33.0%
Price Return 12M -40.5%
Catalyst Signal 0.00
Market Cap $311.1M
TTM Revenue $649.1M
Price / Sales 0.5
ROE -58.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B (3.4) C+ (2.6) C (2.4) B- (2.9) C+ (2.6) C+ (2.8)
2026-11-04 B (3.4) B+ (3.7) C+ (2.5) C (2.2) C+ (2.7) B- (2.9)
2026-10-28 B (3.4) B+ (3.7) C+ (2.5) C (2.2) C+ (2.7) B- (2.9)
2026-10-21 B (3.4) B+ (3.7) C+ (2.5) C- (2.0) C+ (2.6) B- (2.9)
2026-10-14 B (3.4) B+ (3.7) C+ (2.5) C- (2.0) C+ (2.6) B- (2.9)
Page 1 of 5